SCHEMBL5151937

SCHEMBL5151937

CC(=O)Nc1ccccc1OCCCOc1ccc2c3ccccc3n(CC(=O)O)c2c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 2/20 0.51
PSEN1 P49768 7/20 0.48
PSEN2 P49810 7/20 0.48
APH1B Q8WW43 7/20 0.48
NCSTN Q92542 7/20 0.48
APH1A Q96BI3 7/20 0.48
PSENEN Q9NZ42 7/20 0.48
KDM4E B2RXH2 1/20 0.46
BRD4 O60885 1/20 0.45
TSPO P30536 1/20 0.43
TP53 P04637 1/20 0.42
PPARG P37231 2/20 0.42
PPARA Q07869 2/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.42
PPARD Q03181 1/20 0.42
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149523 0.97 SMN1; SMN2 (0.50) SMN1; SMN2LMNAPSEN1PSEN2APH1B
SCHEMBL5151343 0.87 KMT2A (0.53) SMN1; SMN2LMNAPSEN1PSEN2APH1B
SCHEMBL5156647 0.87 MAPT (0.56) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL5149338 0.85 SMN1; SMN2 (0.50) SMN1; SMN2LMNAPSEN1PSEN2APH1B
SCHEMBL5316844 0.85 LMNA (0.51) SMN1; SMN2LMNAPSEN1PSEN2APH1B
SCHEMBL5316092 0.84 PSEN1 (0.52) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL5149628 0.84 PSEN1 (0.50) SMN1; SMN2LMNAPSEN1PSEN2APH1B
SCHEMBL5149343 0.84 MAPT (0.55) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL5317917 0.83 KDM4E (0.60) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5154949 0.82 LMNA (0.54) SMN1; SMN2LMNAPSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US claimed
WO-2007071456-A1 FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-06-28 WO claimed
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US disclosed
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US disclosed
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US disclosed
WO-2007071456-A1 FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor PTGER2, PTGER1, PTGDR2 SMN1; SMN2 3880/4885LMNA 2756/4885PSEN1 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.